# Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

> **NCT03395184** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 244 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** PF-06651600 Placebo
- **DRUG:** PF-06651600
- **DRUG:** Placebo PF-06700841
- **DRUG:** PF-06700841

## Key facts

- **NCT ID:** NCT03395184
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-02
- **Primary completion:** 2023-10-19
- **Final completion:** 2023-10-19
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03395184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03395184, "Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03395184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*